A guidance upgrade and a clinical milestone marked the day's health and biotech action. IXICO led the session with a sharp upward revision to its full-year revenue outlook, while Coiled Therapeutics disclosed meaningful progress on a reformulated oncology candidate ahead of dose expansion.
IXICO upgrades full-year revenue growth forecast to 22%
IXICO (AIM:IXI), the neuroscience imaging specialist, raised its full-year 2026 revenue guidance to at least £8m, implying growth of 22% against a prior forecast of 15%. The upgrade sent shares up 12.0% to 9.1p.
The revision signals stronger-than-anticipated demand for IXICO's imaging analytics services across its clinical trial client base, and represents a meaningful step-up from the company's earlier, more conservative outlook heading into the second half.
Coiled Therapeutics advances softgel formulation ahead of dose expansion
Coiled Therapeutics (AIM:COIL), the oncology-focused biotech, expects to dose the first patients with a new lipid-based softgel formulation of its lead cancer drug this month, as the programme moves into a dose-expansion phase. The company is targeting enrolment of up to 30 patients by the fourth quarter. Shares traded at 9.5p.
The reformulation work represents a step intended to improve the drug's bioavailability profile ahead of broader patient exposure, with the Q4 enrolment target providing a near-term clinical readout horizon for investors tracking the programme.
